Inovio Pharmaceuticals Inc (NASDAQ: INO) closed the day trading at $12.38 down -0.16% from the previous closing price of $12.40. In other words, the price has decreased by -$0.02 from its previous closing price. On the day, 590167 shares were traded.
Ratios:
For a better understanding of INO, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 3.60 and its Current Ratio is at 3.60. In the meantime, Its Debt-to-Equity ratio is 0.26 whereas as Long-Term Debt/Eq ratio is at 0.09.
BofA Securities Downgraded its Neutral to Underperform on November 01, 2022, while the target price for the stock was maintained at $2.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Jun 05 ’23 when Zoth Lota S. sold 5,700 shares for $0.56 per share. The transaction valued at 3,192 led to the insider holds 52,716 shares of the business.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, INO now has a Market Capitalization of 289.33M and an Enterprise Value of 174.24M. For the stock, the TTM Price-to-Sale (P/S) ratio is 348.58 while its Price-to-Book (P/B) ratio in mrq is 2.40. Its current Enterprise Value per Revenue stands at 209.42 whereas that against EBITDA is -1.34.
Stock Price History:
The Beta on a monthly basis for INO is 1.08, which has changed by 17.23% over the last 52 weeks, in comparison to a change of 29.19% over the same period for the S&P500. Over the past 52 weeks, INO has reached a high of $12.79, while it has fallen to a 52-week low of $3.89. The 50-Day Moving Average of the stock is 8.43, while the 200-Day Moving Average is calculated to be 6.21.
Shares Statistics:
Over the past 3-months, INO traded about 534.48K shares per day on average, while over the past 10 days, INO traded about 460.57k shares per day. A total of 23.37M shares are outstanding, with a floating share count of 22.98M. Insiders hold about 1.65% of the company’s shares, while institutions hold 17.93% stake in the company. Shares short for INO as of Feb 29, 2024 were 1.86M with a Short Ratio of 3.48, compared to 1.43M on Jan 31, 2024. Therefore, it implies a Short% of Shares Outstanding of 8.17% and a Short% of Float of 8.23%.
Earnings Estimates
Current recommendations for the stock of the company come from 4 analysts. On average, analysts expect EPS of -$0.99 for the current quarter, with a high estimate of -$0.86 and a low estimate of -$1.17, while EPS last year was -$1.92. The consensus estimate for the next quarter is -$0.97, with high estimates of -$0.82 and low estimates of -$1.15.
Analysts are recommending an EPS of between -$3.2 and -$4.64 for the fiscal current year, implying an average EPS of -$3.93. EPS for the following year is -$3.39, with 3 analysts recommending between -$2.85 and -$4.41.
Revenue Estimates
4 analysts predict $190k in revenue for the current quarter. It ranges from a high estimate of $250k to a low estimate of $100k. As of the current estimate, Inovio Pharmaceuticals Inc’s year-ago sales were $114k, an estimated increase of 66.70% from the year-ago figure. For the next quarter, 4 analysts are estimating revenue of $190k, a decrease of -15.90% less than the figure of $66.70% in the same quarter last year. There is a high estimate of $250k for the next quarter, whereas the lowest estimate is $100k.
